Showing results (251-260 of 6,499) with videos related to
Sort By:
Pageof 650
Cancer Immunology, Immunotherapy : CII|March 21, 2008
Immunization with a GM3 ganglioside nanoparticulated vaccine confers an effector CD8(+) T cells-mediated protection against melanoma B16 challengeZaima Mazorra, Circe Mesa, Audry Fernández, et al.Cancer Immunology, Immunotherapy : CII|March 21, 2008
Virulizin induces production of IL-17E to enhance antitumor activity by recruitment of eosinophils into tumorsTania Benatar, Ming Y Cao, Yoon Lee, et al.Cancer Immunology, Immunotherapy : CII|March 29, 2008
Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunityCédric Ménard, François Martin, Lionel Apetoh, et al.Cancer Immunology, Immunotherapy : CII|March 29, 2008
Targeting activity of a TCR/IL-2 fusion protein against established tumorsJinghai Wen, Xiaoyun Zhu, Bai Liu, et al.Cancer Immunology, Immunotherapy : CII|March 29, 2008
A novel immunoregulatory axis of NKT cell subsets regulating tumor immunityJay A Berzofsky, Masaki TerabeCancer Immunology, Immunotherapy : CII|April 9, 2025
Expression of costimulatory molecule CD70 is prognostic in small cell lung cancerDavid Dora, Zsolt Megyesfalvi, Imre Vörös, et al.Cancer Immunology, Immunotherapy : CII|April 10, 2025
Cohort-based pan-cancer analysis and experimental studies reveal ISG15 gene as a novel biomarker for prognosis and immunotherapy efficacy predictionJingjing Wei, Yingjia Zhuang, Chengfei Jiang, et al.Cancer Immunology, Immunotherapy : CII|April 28, 2025
Cadonilimab, a PD-1/CTLA-4 bispecific antibody in unresectable hepatocellular carcinoma: a real-world studyYilin Wang, Shida Pan, Jiahe Tian, et al.Cancer Immunology, Immunotherapy : CII|April 17, 2025
Durable response to nivolumab in combination with regional hyperthermia in a patient with PD-L1-negative metastatic head and neck squamous cell carcinomaLuc M Berclaz, Anton Burkhard-Meier, Axel Lechner, et al.Cancer Immunology, Immunotherapy : CII|April 17, 2025
Clinical and dynamic circulating cytokines profile features of long-term progression-free survival benefit to immune checkpoint inhibitors in advanced non-small cell lung cancerJia-Yi Deng, Ming Gao, Xue Fan, et al.Pageof 650